Synthesis and Biological Activity of a Cytostatic Inhibitor of MLLr Leukemia Targeting the DOT1L Protein - Archive ouverte HAL Access content directly
Journal Articles Molecules Year : 2021

Synthesis and Biological Activity of a Cytostatic Inhibitor of MLLr Leukemia Targeting the DOT1L Protein

(1, 2) , (1) , (1) , (1, 2) , (1) , (1) , (1) , (3) , (3) , (3) , (3) , (1) , (1)
1
2
3
Dusan Ruzic
Nemanja Djokovic
Teodora Djikić

Abstract

Histone methyltransferase DOT1L catalyzes mono-, di- and trimethylation of histone 3 at lysine residue 79 (H3K79) and hypermethylation of H3K79 has been linked to the development of acute leukemias characterized by the MLL (mixed-lineage leukemia) rearrangements (MLLr cells). The inhibition of H3K79 methylation inhibits MLLr cells proliferation, and an inhibitor specific for DOT1L, pinometostat, was in clinical trials (Phase Ib/II). However, the compound showed poor pharmacological properties. Thus, there is a need to find new potent inhibitors of DOT1L for the treatment of rearranged leukemias. Here we present the design, synthesis, and biological evaluation of a small molecule that inhibits in the nM level the enzymatic activity of hDOT1L, H3K79 methylation in MLLr cells with comparable potency to pinometostat, associated with improved metabolic stability and a characteristic cytostatic effect.
Fichier principal
Vignette du fichier
molecules-26-05300-v2.pdf (6.24 Mo) Télécharger le fichier

Dates and versions

pasteur-03411876 , version 1 (02-11-2021)

Licence

Attribution - CC BY 4.0

Identifiers

Cite

Corentin Bon, Yang Si, Melanie Pernak, Magdalena Barbachowska, Eva Levi-Acobas, et al.. Synthesis and Biological Activity of a Cytostatic Inhibitor of MLLr Leukemia Targeting the DOT1L Protein. Molecules, 2021, Special Issue The Chemical Biology Research in France, 26 (17), pp.5300. ⟨10.3390/molecules26175300⟩. ⟨pasteur-03411876⟩
17 View
16 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More